The bill amends Section 21-31-16.1 of the Rhode Island Food, Drugs, and Cosmetics Act to expand the scope of products that pharmacists can substitute for prescribed medications. The new legal language allows for the substitution of not only generic drugs and biological products but also devices, supplies, and therapeutically equivalent products. The director is required to maintain a list of these therapeutically equivalent products, which must include details such as the product name, dosage, and directions. Additionally, pharmacists are mandated to document any substitutions made from this list and notify the prescribing provider within seven calendar days. However, the bill clarifies that pharmacists are not obligated to use this list, nor are consumers required to accept substitutions based on it.

Furthermore, the bill introduces provisions for the substitution of less expensive devices and supplies, ensuring that these products are approved for the same indications and uses as the prescribed items. The director is tasked with maintaining a current list of interchangeable devices on the Department of Health's website. The act also includes provisions regarding liability, stating that no civil liability will arise from the listing or omission of drugs or products, and it mandates annual reports to the General Assembly regarding approved products and estimated savings to the public. This act is set to take effect on January 1, 2026.